Lung cancer vaccine shows promise in early prevention trial
NCT ID NCT04298606
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a vaccine called CIMAvax-EGF in 20 people at high risk for lung cancer or survivors at risk of recurrence. The vaccine works by helping the body make antibodies against a protein that can fuel cancer growth. Researchers checked for side effects and measured immune response to see if the vaccine might prevent lung cancer from starting or coming back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart breathing machines at home: a new way to predict COPD crises?
- Breathing easy? new X-Ray method may spot COPD decline early
- AI could outsmart bacteria: a smarter way to choose antibiotics?
- Breathing technique may outperform spirometry for smog pneumonia recovery
- Could a common heart drug cut COPD hospitalizations?
- A gentle touch against coughs and colds: could manual therapy shorten respiratory illness?